Why cell therapy manufacture is a team sportLouis van de Wiel, Vice President, Site Head EU Manufacturing, Kite, a Gilead Company, reveals the complexity that Share XWhy cell therapy manufacture is a team sporthttps://pharmaphorum.com/market-access-2/why-cell-therapy-manufacture-is-a-team-sport/
Pfizer cut vaccine production targets because of raw material shortage – reportsPfizer slashed its production targets for its COVID-19 vaccine because of a lack of raw materials for its Share XPfizer cut vaccine production targets because of raw material shortage – reportshttps://pharmaphorum.com/news/pfizer-cut-vaccine-production-targets-because-of-raw-material-shortage-reports/
BioNTech, InstaDeep plan joint lab for AI researchBioNTech may be deeply ensconced in the latter stages of its bid to bring a COVID-19 vaccine to Share XBioNTech, InstaDeep plan joint lab for AI researchhttps://pharmaphorum.com/news/biontech-instadeep-plan-joint-lab-for-ai-research/
Could an FDA inspection scupper CVR deadline for BMS’ liso-cel?Bristol-Myers Squibb posted a solid set of financial results for the third quarter, but shares slid on investor Share XCould an FDA inspection scupper CVR deadline for BMS’ liso-cel?https://pharmaphorum.com/news/could-an-fda-inspection-scupper-cvr-deadline-for-bms-liso-cel/
Pfizer ‘ready to roll’ if BioNTech COVID-19 shot is approvedPfizer now has hundreds of thousands of doses of BioNTech’s COVID-19 vaccine coming off the production line at Share XPfizer ‘ready to roll’ if BioNTech COVID-19 shot is approvedhttps://pharmaphorum.com/news/pfizer-ready-to-roll-if-biontech-covid-19-shot-is-approved/
Lilly pauses COVID-19 antibody trial after factory hits trouble with FDAEli Lilly has put a clinical trial of its COVID-19 antibody therapy on hold after FDA inspectors found Share XLilly pauses COVID-19 antibody trial after factory hits trouble with FDAhttps://pharmaphorum.com/news/lilly-pauses-covid-19-antibody-trial-after-factory-hits-trouble-with-fda/
BioNTech, Lilly shore up manufacturing capacity for their COVID-19 medsWith vaccines and drugs for COVID-19 now in late-stage development, companies are moving swiftly to lay down the Share XBioNTech, Lilly shore up manufacturing capacity for their COVID-19 medshttps://pharmaphorum.com/news/biontech-lilly-shore-up-manufacturing-capacity-for-their-covid-19-meds/
Sanofi set to spin off API business late next year – reportSanofi is to begin preparations in autumn to spin off its active ingredients business and is lining up a potential Share XSanofi set to spin off API business late next year – reporthttps://pharmaphorum.com/news/sanofi-set-to-spin-off-api-business-late-next-year-report/
Gilead working with generics firms to boost global supply of COVID-19 drugGilead has outlined plans to work with generics firms to rapidly increase production of its COVID-19 drug remdesivir to meet Share XGilead working with generics firms to boost global supply of COVID-19 drughttps://pharmaphorum.com/news/gilead-working-with-generics-firms-to-boost-global-supply-of-covid-19-drug/
